Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 265

The recommendations for pneumococcal vaccines are based on evidence and probable life expectancy in various categories. Although the pneumococcal vaccine is less effective in producing protective antibody levels in older adults than young adults, it’s still effective in reducing the incidence of pneumococcal bacteremia in high‐risk patients.

Currently, most organizations recommend one dose of Prevnar 13 followed by one dose of 23 valent pneumococcal vaccine one year apart, after age 65. If the patient has had a prior 23 valent pneumococcal vaccine, only Prevnar 13 should be given. There are no recommendations about re‐immunization.³³